Qualigen Therapeutics, INC. (AIXC) — 10-Q Filings

10-Q Filings (6)

• Qualigen's Cash Soars 3200% on $41M Faraday-Backed Private Placement — Nov 14, 2025 Risk: medium
  Qualigen Therapeutics, Inc. (AIXC) reported a net loss of $6,369,407 for the nine months ended September 30, 2025, an increase from a net loss of $5,303,368 in
• AIXC's Net Loss Widens 20% Amid Soaring G&A, Cash Dwindles — Aug 14, 2025 Risk: high
  Qualigen Therapeutics, Inc. (AIXC) reported a significant increase in net loss for the six months ended June 30, 2025, reaching $4,331,588, up from $3,609,309 i
• Qualigen Narrows Q1 Loss to $2.2M Amidst Ongoing Capital Raises — Jul 21, 2025 Risk: high
  Qualigen Therapeutics, Inc. (AIXC) reported a net loss of $2.2 million for the three months ended March 31, 2025, a significant improvement from the $4.1 millio
• Qualigen Therapeutics Files Q3 2024 10-Q Report — Nov 14, 2024 Risk: low
  Qualigen Therapeutics, Inc. filed its Q3 10-Q report for the period ending September 30, 2024. The company, formerly Ritter Pharmaceuticals Inc., is incorporate
• Qualigen Therapeutics Files Q2 2024 10-Q — Aug 14, 2024 Risk: medium
  Qualigen Therapeutics, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported financial results and operational updates. Specific financi
• Qualigen Therapeutics Files Q1 2024 10-Q — Jul 2, 2024 Risk: medium
  Qualigen Therapeutics, Inc. filed its 10-Q for the period ending March 31, 2024. The company reported financial results for the first quarter of 2024, detailing

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX